Compare · AZN vs IMMX
AZN vs IMMX
Side-by-side comparison of AstraZeneca PLC (AZN) and Immix Biopharma Inc. (IMMX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and IMMX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 366.1x IMMX ($715.4M).
- Over the past year, AZN is down 10.3% and IMMX is up 236.1% - IMMX leads by 246.4 points.
- AZN has hit the wire 12 times in the past 4 weeks while IMMX has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 4 for IMMX).
- Company
- AstraZeneca PLC
- Immix Biopharma Inc.
- Price
- $168.85-0.24%
- $10.25+2.04%
- Market cap
- $261.92B
- $715.4M
- 1M return
- -5.56%
- +17.14%
- 1Y return
- -10.32%
- +236.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 4
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Immix Biopharma Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest IMMX
- BofA Securities initiated coverage on Immix Biopharma with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Immix Biopharma Inc.
- Immix Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Chang Nancy T was granted 6,250 shares, increasing direct ownership by 1% to 428,190 units (SEC Form 4)
- SEC Form 4 filed by CFO, President Morris Gabriel S
- Director Adams Helen C. was granted 6,250 shares, increasing direct ownership by 4% to 181,004 units (SEC Form 4)
- Director Marquet Magda was granted 6,250 shares, increasing direct ownership by 14% to 52,342 units (SEC Form 4)
- Director Ng Carey was granted 6,250 shares, increasing direct ownership by 31% to 26,250 units (SEC Form 4)
- Director Chudnovsky Yekaterina was granted 6,250 shares (SEC Form 4)
- Director Buchan Jane was granted 6,250 shares, increasing direct ownership by 28% to 28,705 units (SEC Form 4)